Answers are grounded in this paper and cite their sources.
Patients with hairy-cell leukemia lacking the BRAF V600E mutation often have a BRAF deletion or activating mutation in MAP2K1 , with a poor response to standard therapy. Dabrafenib plus trametinib was active in one patient.
No takes yet. Share an insight, caveat, or question.
Santi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: